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Abstract
Background: Renal toxicity has been reported with bisphosphonates such as pamidronate and zolidronate but not
with ibandronate, in the treatment of breast cancer patients with bone metastasis. One of the patterns of
bisphosphonate-induced nephrotoxicity is focal segmental glomerulosclerosis (FSGS) or its morphological variant,
collapsing focal segmental glomerulosclerosis (CFSGS).
Case presentation: We describe a breast cancer patient who developed heavy proteinuria (protein/creatinine ratio
9.1) and nephrotic syndrome following treatment with oral ibandronate for 29 months. CFSGS was proven by
biopsy. There was no improvement 1 month after ibandronate was discontinued. Prednisone and tacrolimus were
started and she experienced a decreased in proteinuria.
Conclusion: In patient who develops ibandronate-associated CFSGS, proteinuria appears to be at least partially
reversible with the treatment of prednisone and/or tacrolimus if the syndrome is recognized early and ibandronate
is stopped.
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Background
Bisphosphonates are widely used in the treatment of pa-
tients with metastatic bone diseases. They play an im-
portant role in decreasing bone morbidity, preventing
bone complications and managing bone pain. Further-
more, emerging evidence suggests that bisphosphonates
may potentially inhibit angiogenesis and tumor cell inva-
sion, induce apoptosis in tumor cells and have immuno-
modulatory effects [1, 2]. They have been increasingly
studied in the adjuvant setting of breast cancer treat-
ment and have showed some promising effects [3–5].
Bisphosphonates can be administered either orally or
intravenously. Oral ibandronate was evaluated in the
German Intergroup Node-Positive (GAIN) study, in
which patients receiving one of two dose-dense chemo-
therapy regimens were randomized to 2 years of oral
ibandronate versus placebo [6]. The first interim efficacy
analysis was also presented at San Antonio Breast
Cancer Symposium in December 2011. There was no
difference in 3 year disease free survival or overall sur-
vival. The Southwest Oncology Group (SWOG) S0307
trial is a comparison of three different bisphospho-
nates in the adjuvant breast cancer setting. This trial
randomized 6,000 women with stage I- III breast can-
cer receiving standard adjuvant therapy to oral clodro-
nate (1600 mg, daily) versus oral ibandronate (50 mg,
daily) versus zoledronate (4 mg intravenously, monthly
for 6 months, then every 3 months), all for 3 years
duration. This trial recently closed to accrual and will
provide further data on the utility of bisphosphonates
in the adjuvant setting.
Drug-related side effects are limiting factors to the use
of bisphosphonates. Bisphosphonates have been associ-
ated with deterioration of renal function and histopatho-
logical changes in the kidney. Available data suggest that
pamidronate and zolidronate, but not ibandronate, are
associated with nephrotoxicity in the treatment of pa-
tients with malignant disease [7]. One of the patterns of
nephrotoxicity with bisphophonates is the development
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of the focal segmental glomerulosclerosis (FSGS) or its
morphological variant the collapsing focal segmental
glomerulosclerosis (CFSGS), which typically presents
with nephrotic syndrome and renal insufficiency [7]. To
our knowledge, no patients with CFSGS and nephrotic
syndrome associated with ibandronate have been de-
scribed in the literature before.
Case presentation
A 44-year-old Caucasian female with a family history of
breast cancer and multiple myeloma was seen in clinic
for right breast, stage I, triple negative invasive ductal
carcinoma. She had undergone a lumpectomy followed
by adjuvant dose-dense Adriamycin, Cyclophosphamide
(AC) and paclitaxel chemotherapy and radiation. She
was enrolled in the SWOG S0370 study and randomized
to the oral ibandronate arm and had been taking oral
ibandronate 50 mg once daily since December 2008 with
stop date scheduled for December 2011. In May 2011,
she presented with new onset lower extremity edema.
Laboratory tests at the time revealed heavy proteinuria
with a protein/creatinine ratio 9.1 (g/g), hypoalbuminaemia
(2.1 g/l) and hypercholesterolaemia (14 mmol/l) with no
hematuria and normal serum creatinine (0.7 mg/dl) which
had been consistently normal before. She had no hyperten-
sion history. A diagnosis of nephrotic syndrome was made.
Serological evaluation for HIV, hepatitis C, hepatitis B
virus, antibodies to nuclear antigens (ANA), rheumatoid
factor, anti-neutrophil cytoplasmic antibody (anti-PR3
and anti-MPO), anti cardiolipin, and anti beta 2 glyco-
protein 1 were negative. Values of serum complement
(total, C3 and C4), free light chain (kappa and lambda),
protein electrophoresis, immnofixation,beta 2 micro-
globulin and immunoglobulin (A, G and M) were within
normal range. There were no spikes by urine and serum
protein electrophoresis.
A renal biopsy was performed and specimens were
sent for light, immunofluorescent and electron micros-
copy. The biopsy consisted of portions of cortex and me-
dulla, containing 10 to 15 glomeruli per level section.
None of the glomeruli were globally sclerosed. About
13–40 % of glomeruli per level section showed segmen-
tal obliteration of capillary loops with accumulation of
extracellular matrix, hyaline or foam cells in the sclerotic
regions and adhesion to Bowman’s capsule, consistent
with focal and segmental glomerulosclerosis (FSGS)
(Fig. 1a). Up to two glomeruli with FSGS showed seg-
mental collapse of capillary tufts with proliferation of
overlying epithelial cells, characteristic of collapsing glo-
merulopathy (Fig. 1b). No additional lesion was found in
the glomeruli. The rest of renal parenchyma showed
mild interstitial fibrosis and tubular atrophy, mild and
scattered predominantly mononuclear interstitial, in-
flammatory infiltrate, diffuse, mild interstitial edema and
occasional tubulitis. Arterioles were unremarkable, but
interlobular arteries showed moderate intimal fibrosis.
Immunofluorescence studies were unremarkable with no
significant glomerular staining for IgG, IgA, IgM, C3,
C1q, fibrinogen, kappa or lambda light chains or albu-
min. Electron microscopy showed extensive effacement
of foot processes involving about 60 to 70 % of capillary
surface area (Fig. 1c). No electron dense deposit was
identified. After the diagnosis of nephrotic syndrome,
ibandronate was discontinued. She initially underwent
treatment with lisinopril, simvastatin and furosemide.
However, after one month, she had no improvement of
protenuria. Prednisone was started at 60 mg daily. About
one month later, urine protein/creatinine ratio was re-
duced to 4.9 g/g, thus indicative of some improvement
Fig. 1 a A glomerulus with FSGS. The red arrow marks the segmentally sclerosed region with obliteration of capillary tuft, hyaline deposition and
adhesion to Bowman’s capsule. Jones methenamine silver, 40x objective. b A glomerulus with collapsing variant of FSGS. There is almost diffuse
collapse of capillary loops with proliferation of overlying epithelial cells (yellow arrow). Jones methenamine silver, 40x objective. c An electron micrograph
shows extensive effacement of foot processes (black arrows) over a capillary loop (cap) with corrugated glomerular basement membrane.
4800 X magnification
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but still within the nephrotic range. Therefore, a calcine-
urin inhibitor, tacrolimus 1 mg twice daily was started in
August 2011 and continued through October 2013.
Prednisone was tapered off after 7 months in March
2012. Creatinine was relatively stable throughout treat-
ment and Estimated Glomerular Filtration Rate (eGFR)
calculated by Modification of Diet in Renal Disease
(MDRD) equation was normal. She is currently on lisi-
nopril 40 mg daily with mild proteinuria (protein/cre-
atinine ratio of 0.5) at the time of this report.
Discussion
We report a rare case of collapsing FSGS and nephrotic
syndrome associated with the administration of oral
ibandronate. Ibandronate is a single nitrogen-containing
bisphosphonate with higher comparative protein binding
and shorter comparative renal tissue half life than other
bisphosphonates. It is Food and Drug Administration
approved for treatment of post-menopausal osteoporosis
(PMO). Outside the United States, ibandronate is ap-
proved by the European Union for the treatment of
PMO and malignancy-associated bone disease.
Ibandronate appears to have a safer renal profile with
no evidence of nephrotoxicity. Intravenous ibandronate
given over 15 min, 60 min or 15–30 s did not have renal
toxicity, even in patients with preexisting hypertension
or diabetes, although follow up is short [8–10]. Fourteen
patients who received a median of 16 monthly infusions
of ibandronate have no renal toxicity [11]. With 44
patients and 524 cycles of oral idandronate with a me-
dian of 12 monthly cycles, there is no deterioration of
renal function [12]. In patients with preexisting renal
impairment, there is no acute nephrotoxicity with iban-
dronate [13]. Results from clinical trials indicate that the
renal safety profile of intravenous and oral ibandronate
is similar to that of placebo for up to 4 years treatment
in metastatic breast cancer [14, 15].
The renal biopsy findings in our patient displayed
FSGS with collapsing features and extensive foot process
effacement, consistent with significant podocyte injury.
Pamidronate toxicity targets podocytes, while some
cases of pamidronate-associated toxic acute tubular
necrosis (ATN) have been reported [16]. Zoledronate ap-
pears to mainly target tubular epithelium, resulting in a
pattern of toxic ATN, but zoledronate-associated col-
lapsing FSGS has also been reported [17]. Therefore,
renal injury of intravenous bisphosphonates is likely to
be very complex and overlap between different agents.
We did not identify significant acute tubular injury in
the current biopsy.
The renal tolerability of oral bisphosphonates is rela-
tively good. However, nephrotoxicity has been reported
with oral bisphosphonates. Miura et al. reported a single
case of massive proteinuria and acute renal failure after
alendronate administration in a patient with focal seg-
mental glomerulosclerosis [18]. Stratton et al. reported
two cases of relapse of steroid-dependent nephrotic syn-
drome triggered by etidronate [19]. Proteinuria is thus a
known feature of bisphosphonate-associated nephrotox-
icity. In many cases, nephrotic syndrome associated with
bisphosphonate is partially or completely reversible fol-
lowing discontinuation of bisphosphonate [18–20].
The frequency of proteinuria in breast cancer patients
with metastatic bone disease receiving intravenous iban-
dronate was similar to those receiving placebo or no
clinical relevant changes from baseline in 2 randomized
trials [10, 21]. However the numbers of patients were
limited and the study periods were only 3 and 6 months
respectively. Transient proteinuria after the treatment of
intravenous ibandronate for metastatic breast cancer has
been reported before [22].
The American Society of Clinical Oncology 2011 Clinical
Practice Guideline Update committee recommends that
serum creatinine should be monitored before each dose
of pamidronate or zoledronic acid per FDA-approved
labeling [23]. Serum calcium, electrolytes, phosphate,
magnesium, and hematocrit/hemoglobin should also be
monitored regularly. Therefore, since proteinuria was
not monitored commonly in the patients treated with
long-term intravenous and oral ibandronate before, the
renal toxicity of ibandronate could be underestimated.
The etiology for the difference in nephrotoxic poten-
tial is not entirely clear, but could relate to pharmacoki-
netic differences. Ibandronate is more highly protein
bound, which may limit renal exposure of free drug. The
renal tissue half-life of ibandronate is much shorter than
zoledronate [24].
Conclusion
We report an unusual case of oral ibandronate-associated
CFSGS and nephrotic syndrome. Proteinuria appears to be
partially reversible with the treatment of prednisone and/or
tacrolimus if the syndrome is recognized early and ibandro-
nate is stopped. We did not have a follow up biopsy to con-
firm if the observed improvement in proteinuria was
associated with histological amelioration of FSGS or foot
process effacement. We recommend monitoring protein-
uria for earlier detection of worsening renal function in pa-
tients with long-term treatment of oral ibandronate. Renal
biopsy is a key procedure for diagnosis and treatment.
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